- Tytuł:
- Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
- Autorzy:
- Źródło:
- In The Lancet 11 June 2022 399(10342):2200-2211
Czasopismo naukowe